Martha J. Carter Joins Essential Therapeutics as Senior Vice President of Regulatory Affairs
Friday October 4, 7:00 am ET
WALTHAM, Mass., Oct. 4 /PRNewswire-FirstCall/ -- Essential Therapeutics, Inc. (Nasdaq: ETRX - News) today announced the appointment of Martha J. Carter, RAC as Senior Vice President of Regulatory Affairs. Essential Therapeutics has emerging clinical and preclinical programs concentrated in hematology/oncology and infectious disease therapeutic areas. Ms. Carter will be responsible for regulatory affairs worldwide at Essential Therapeutics.
Ms. Carter has more than 20 years experience in regulatory affairs managing prescription and over-the-counter drugs, biologics, biotechnology products and medical devices. During the last four years, Ms. Carter worked at GelTex Pharmaceuticals, where she supervised the company's regulatory and quality functions for commercial and investigational drug products. In her role as Vice President, Regulatory Affairs, she handled all communication between GelTex and the Food and Drug Administration. Her responsibilities included managing regulatory submission and compliance activities, and supporting the manufacture of APIs and dosage forms.
"We are very pleased to welcome Martha Carter, who brings 20 years of accomplishment in regulatory affairs within the life sciences industry," commented Mark Skaletsky, President, Chairman of the Board and Chief Executive Officer at Essential Therapeutics. "We believe her expertise will be critical to the Company's regular, ongoing interactions with the FDA for its lead programs in hematology/oncology and infectious disease."
Ms. Carter said, "I look forward to working with the team at Essential Therapeutics, which has put together one of the most exciting programs to advance breakthrough products addressing serious medical needs."
Prior to joining GelTex, Ms. Carter served at Genetics Institute as Director of Regulatory Affairs, where she directed activities for recombinant biologicals and a combination Class III medical device. Previously, she held positions of increasing responsibilities at ImmuLogic Pharmaceutical Corporation and Serono Laboratories, attaining the position of Vice President of Regulatory Affairs. Ms. Carter has served on the Board of Directors of the Regulatory Affairs Professionals Society, and was Chair in 1999.
Ms. Carter received her B.A. degree in Biology from Northeastern University. In addition, she attended the Massachusetts College of Pharmacy and Allied Health Sciences where she completed the didactic portion of the Master of Science degree in Therapeutics.
About Essential Therapeutics
Essential Therapeutics, Inc. is committed to the development of breakthrough biopharmaceutical products for the treatment of life-threatening diseases. With an emerging pipeline of lead programs and product candidates in the anti-infective and hematology/oncology therapy areas, Essential Therapeutics is dedicated to commercializing novel small molecule products addressing important unmet therapeutic needs. Additional information on Essential Therapeutics can be obtained at essentialtherapeutics.com.
Statements contained herein that are not historical fact may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements made by Essential Therapeutics. These include, but are not limited to, Essential Therapeutics' ability to: (i) progress its therapeutic pipeline; (ii) develop breakthrough biopharmaceutical products; and (iii) successfully commercialize products. For a discussion of other risks and uncertainties affecting Essential Therapeutics' business, see Essential's Quarterly Report on Form 10-Q for the quarter ended June 30, 2002. Actual results and timing of certain events could differ materially from those indicated in the forward-looking statements as a result of these or other factors.
--------------------------------------------------------------------------------
Source: Essential Therapeutics, Inc. |
